Paul Nghiem on Muck Rack

Paul Nghiem

Seattle
As seen in: MSN, Nature, PNAS, JAMA (The Journal of the American Medical Association), JAMA Oncology, The New England Journal of Medicine, Medical Xpress, Prevention, Newswise, Healio and
Dermatologist/cancer biologist. Runs lab using immune system to fight a nasty virus-driven skin cancer. Two boys, a pandemic puppy & chamber music for fun.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Paul

Contact Paul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

What’s Next in Dermatology? Dermatologists Weigh In On 2026

|
By Linda Gold, Lawrence F. Eichenfield, Neal Bhatia, Dawn Z. Eichenfield, Philip Mease, Paul Nghiem, Walter Liszewski
| consultantlive.com
As 2026 begins, clinicians in dermatology are looking ahead to a year defined by expanding oral therapeutics, immunologic insights, next-generation biologics, and the increasing artificial intelligence (AI) integration into clinical settings. At the 2026 Maui Derm Hawaii meeting, the HCPLive team spoke on-site with several leaders in the field of skin health about new data and therapeutic advances they anticipate shaping the field in the year ahead.
Open in Who Shared View Duplicates (2) Issue with article?

CLINICAL BENEFIT OF ADDING RADIATION FOR IMMUNE CHECKPOINT INHIBITOR-REFRACTORY MERKEL CELL CARCINOMA: A 27-PATIENT ANALYSIS

|
By Seattle WA, Albert Einstein College, Paul Nghiem
| jidonline.org
Keywords Merkel cell carcinoma Immunotherapy radiation therapy combination therapy Abbreviations MCC (Merkel cell carcinoma) ICI (immune checkpoint inhibitor) RT (radiation therapy) PFS (progression-free survival) HR (hazard ratio) Gy (Gray) OS (overall survival) CR (complete response) PR (partial response) PD (progressive disease) SD (stable disease) AE (adverse events) Get full text access Log in, subscribe or purchase for full access. References 1. Becker, J.C. ∙ Stang, A. ∙ DeCaprio, J.A. ...
Open in Who Shared Issue with article?

New Therapeutic Options in Cutaneous Oncology for 2026, With Paul Nghiem, MD, PhD

|
By Paul Nghiem
| consultantlive.com
During the 2026 Maui Derm Hawaii conference, HCPLive spoke with Paul Nghiem, MD, PhD, of the University of Washington Medicine South Lake Union (SLU) and the Fred Hutch Cancer Center, regarding the takeaways from his conference talk titled ‘Cutaneous Oncology Update 2026.1 The presenters of this talk highlighted management strategies and therapeutic agents for actinic keratoses (AKs) and other conditions.
Open in Who Shared View Duplicates (2) Issue with article?
See all 27 licensed articles (36 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified